Showing results (2001-2010 of 2,232) with videos related to

Sort By:
Pageof 224
Lung Cancer (Amsterdam, Netherlands)|August 10, 2018
Factors associated with gene aberration test status and treatment decision in patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer: A multicenter survey in China (CTONG 1506)Yong Song, Qing Zhou, Xin Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 2, 2015
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and ChemotherapyTony Mok, Yi-Long Wu, Jin Soo Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2022
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 StudyGilberto de Castro, Iveta Kudaba, Yi-Long Wu, et al.
BMC Cancer|February 26, 2016
Distribution and prognosis of uncommon metastases from non-small cell lung cancerFei-Yu Niu, Qing Zhou, Jin-Ji Yang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 12, 2017
Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic StrategiesZhong-Yi Dong, Chao Zhang, Yu-Fa Li, et al.
Signal Transduction and Targeted Therapy|June 16, 2026
Neoadjuvant retlirafusp alfa (anti-PD-L1/TGF-β bifunctional fusion protein) with or without chemotherapy in unresectable stage III non-small cell lung cancer: updated results from the phase 2 TRAILBLAZER trialYi Pan, Xuening Yang, Qing Zhou, et al.
Cancers|January 8, 2023
Longitudinal Plasma Proteomics-Derived Biomarkers Predict Response to MET Inhibitors for MET-Dysregulated NSCLCGuang-Ling Jie, Lun-Xi Peng, Mei-Mei Zheng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2011
Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancerQing Zhou, Xu-Chao Zhang, Zhi-Hong Chen, et al.
Biotechnology Progress|April 6, 2002
Development of mammalian serum albumin affinity purification media by peptide phage displayAaron K Sato, Daniel J Sexton, Lee A Morganelli, et al.
European Journal of Cancer (Oxford, England : 1990)|April 21, 2021
Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatmentsMei-Mei Zheng, Hai-Yan Tu, Jin-Ji Yang, et al.
Pageof 224